Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2006

View Archived Issues

Large trials support regulatory filings for paliperidone in schizophrenia

Potential for interactions with indiplon evaluated

Lisdexamfetamine pharmacokinetics studied in animals and humans

Oral AFPep effective in models of breast cancer

E75 vaccine reduces regulatory T cells in breast cancer patients

Vertex reflects on quarter

GE Healthcare exercises option to U.S. rights for Hexvix

Alliance updates Oxygent progression for postoperative ileus

Amgen to develop Predix's S1P1 modulators under new agreement

Negative opinion handed down for Valdoxan/Thymanax in Europe

Zileuton CR filed for approval

Daiichi acquires Japanese rights to nimotuzumab

Momenta files IND for phase I study of anticoagulant M-118

Singapore's DSO National Laboratories to study Viprovex in acute melioidosis

Sabarep makes good progress

WX-UK1 successfully completes two phase Ib studies in tumor patients

XL-647 begins phase II study in NSCLC

Dacogen receives orphan drug designation for AML in Europe

Transacin eligible for European submission via centralized procedure

AK-1015 cleared to begin pivotal trial for ocular anesthesia

IND approval for U.S. study of ONO-4538/MDX-1106

Keppra intravenous formulation approved in U.S.

FDA approves MoviPrep

ATryn approved for use in E.U.

Santen files for Japanese approval of DE-085

Recent patents claim novel agents for respiratory disorders

Novel renin inhibitors emerge from Novartis R&D

Recent Pfizer patent reports new PET diagnostic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...